Obesity Classes and Management
Obesity is classified into three main classes based on BMI: class I (BMI 30-34.9), class II (BMI 35-39.9), and class III (BMI ≥40), with management strategies intensifying as BMI increases to address the escalating health risks associated with higher obesity classes. 1
Classification of Obesity
Body Mass Index (BMI) is the most widely used method to classify obesity, calculated as weight in kilograms divided by height in meters squared (kg/m²):
- Underweight: BMI < 18.5 kg/m²
- Normal weight: BMI 18.5-24.9 kg/m²
- Overweight: BMI 25-29.9 kg/m²
- Class I obesity: BMI 30-34.9 kg/m²
- Class II obesity: BMI 35-39.9 kg/m²
- Class III obesity: BMI ≥40 kg/m² 1
Important Considerations in Classification
- Ethnic variations: Asian populations may require lower BMI thresholds (≥25 or ≥27.5) for obesity diagnosis due to higher cardiometabolic risk at lower BMI levels 1
- Additional measurements: Waist circumference should be used alongside BMI, especially for BMI 25-34.9, with high-risk thresholds being ≥102 cm (>40 inches) for men and ≥88 cm (>35 inches) for women 1
- Edmonton Obesity Staging System: Classifies risk based on factors independent of BMI; higher severity scores are associated with increased all-cause mortality (hazard ratio 2.69) 1
Health Risks Associated with Obesity
Obesity significantly increases morbidity and mortality through:
- Cardiovascular disease: Men with BMI 30-39.9 have cardiovascular event rates of 20.21 per 1000 person-years vs. 13.72 for normal BMI; women with BMI 30-39.9 have rates of 9.97 vs. 6.37 for normal BMI 1
- Metabolic complications: Type 2 diabetes, hypertension, dyslipidemia
- Mechanical complications: Obstructive sleep apnea, osteoarthritis
- Other conditions: Asthma, nonalcoholic fatty liver disease 1
Management Approach by Obesity Class
For All Obesity Classes (I-III)
Behavioral interventions:
Nutritional therapy:
- Reduce total caloric intake
- Dietary strategies based on patient preferences 1
Physical activity:
- Regular exercise (even without calorie reduction typically causes 2-3 kg weight loss)
- Critical for weight maintenance 1
For Class II Obesity (BMI 35-39.9) with Comorbidities and Class III Obesity (BMI ≥40)
In addition to the above interventions:
Pharmacotherapy:
- FDA-approved medications for long-term use:
- GLP-1 agonists (semaglutide, liraglutide)
- Tirzepatide (GIP/GLP-1 agonist) - most effective with 21% weight loss at 72 weeks
- Phentermine-topiramate
- Naltrexone-bupropion
- Orlistat 1
- FDA-approved medications for long-term use:
Bariatric procedures:
- Endoscopic procedures: intragastric balloon, endoscopic sleeve gastroplasty (10-13% weight loss)
- Bariatric surgeries: laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass (25-30% weight loss at 12 months) 1
Monitoring and Follow-up
- For all patients with obesity: measure height, weight, BMI, and body fat distribution at least annually 1
- During active weight management: increase monitoring to at least every 3 months 1
- Maintain long-term follow-up as weight regain occurs in ≥25% of participants at 2-year follow-up 1
Special Considerations
- Medication review: Evaluate and consider alternatives to medications that cause weight gain (e.g., certain antidepressants like mirtazapine, amitriptyline; antihyperglycemics like glyburide or insulin) 1
- Person-centered approach: Use person-first language (e.g., "person with obesity" rather than "obese person") 1
- Privacy: Ensure accommodations are made for privacy during anthropometric measurements 1
Pitfalls to Avoid
- Relying solely on BMI: BMI does not directly measure adiposity or account for individual differences in risk 1
- Ignoring weight distribution: Central adiposity increases cardiovascular risk independent of BMI 1
- Underestimating the importance of sustained intervention: Weight regain is common without ongoing support 1
- Neglecting psychological aspects: Weight stigma and bias can impede effective treatment 2
By implementing a structured approach to obesity management based on obesity class and individual risk factors, clinicians can significantly improve morbidity, mortality, and quality of life outcomes for patients with obesity.